INS 2017: Saluda's Closed-Loop Spinal Cord Stim Tech Sparks GSK-VC Interest; Solid Preliminary Data
Executive Summary
Australian closed-loop neuromodulation specialist Saluda Medical looks to be going from strength to strength as it welcomes a $40m injection of fresh funds from investors including the GSK fund, Action Potential Venture Capital. The investment will further support Saluda's expanding clinical activities, from which positive three- and six-month data on the safety and performance of its Evoke closed-loop spinal cord stimulator were presented at the recent 13th International Neuromodulation Society congress in Edinburgh, Scotland.
You may also be interested in...
VC Deals Analysis: From Famine To Feast, 2017 Bloats With May Haul
The venture financing climate has been somewhat dull so far this year but the investment activity levels enjoyed a much-needed boost in May. The month's haul of transactions not only brought in the quantity – with the highest deal volume to date – but also quality, high-value rounds.
Could Alcon's CyPass Trouble Be Boon For Glaukos – Or Bust For MIGS?
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roche Dx' EMEA Head To Take Charge After Diggelmann Departs
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.